The FDA approved Boehringer's nerandomilast, now Jascayd, as the first new U.S. treatment for idiopathic pulmonary fibrosis ...

In just over a month, one of the largest gatherings of pulmonary fibrosis (PF) patients, caregivers, and health professionals will take place in Chicago, at the Pulmonary Fibrosis Foundation (PFF) ...

Nerandomilast appears to reduce the risk of death in people with IPF and PPF, according to analyses of clinical trial data.

Columnist Sam Kirton's diagnostic journey was relatively short compared with that of other idiopathic pulmonary fibrosis (IPF) patients.

GRI-0621, an experimental oral therapy for idiopathic pulmonary fibrosis (IPF), may stabilize lung function, according to an interim analysis of an ongoing Phase 2a study. “The FVC data after 6 weeks ...

I’m at it again; I’m job hunting, or seeking employment, if you will. But this time, the search carries more weight. It’s not just about finding work; it’s about reclaiming a part of myself that I ...

The inhalation therapy Tyvaso (treprostinil) significantly improved a measure of lung function for people with idiopathic pulmonary fibrosis (IPF) in a Phase 3 clinical trial. The top-line result ...

Treatment with GRI Bio‘s investigational oral therapy GRI-0621 appears to reduce markers of fibrosis, or scarring, in people with idiopathic pulmonary fibrosis (IPF), according to an interim analysis ...

Fast shallow breathing (tachypnea) is one of several breathing difficulties experienced by pulmonary fibrosis (PF) patients. Breathing problems are common in PF because the disease causes progressive ...